Immix Biopharma Company Insiders

Immix Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.5685) % which means that it has lost $0.5685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0381) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.81 in 2024. Return On Capital Employed is likely to rise to -0.95 in 2024. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 144.3 K in 2024, whereas Total Assets are likely to drop slightly above 12 M in 2024. Common Stock Shares Outstanding is likely to drop to about 13.1 M in 2024. Net Loss is likely to drop to about (7.8 M) in 2024

Immix Biopharma Workforce Comparison

Immix Biopharma Insider Trading

Immix Biopharma Notable Stakeholders

The success or failure of an entity such as Immix Biopharma often depends on how effective the management is. Immix Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Immix Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immix Biopharma. Check Immix Biopharma's Beneish M Score to see the likelihood of Immix Biopharma's management manipulating its earnings.

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.